×

Caliber Imaging & Diagnostics to Exhibit VivaScope(R) System at Society for Neuroscience 2014 Annual Meeting in Washington, DC on November 16-19

BOSTON and ROCHESTER, N.Y., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Caliber Imaging & Diagnostics (OTCQB:LCDX), formerly Lucid, Inc., announced it will exhibit its VivaScope® system at the Society for Neuroscience 2014 Annual Meeting at the Walter E. Washington Convention Center in Washington, DC on November 16-19. The Company will be exhibiting in Booth #1906.

L. Michael Hone, CEO of Caliber I.D., said, "The Society for Neuroscience conference is one of the premiere events for the life science industry. There are many neuroscientists who could find our technology useful in their research, for example the use of confocal microscopy in the imaging of surface microvasculature of the cerebral cortex. This is an important opportunity to showcase our innovative products to many more potential customers with an interest in the latest developments in the field. Our products can enhance the capabilities of researchers in this sector."

The Society for Neuroscience Annual Meeting is the premier venue for neuroscientists to present emerging science, learn from experts, forge collaborations with peers, explore new tools and technologies, and advance careers. More than 30,000 colleagues from more than 80 countries are expected to attend the world's largest marketplace of ideas and tools for global neuroscience.

About Caliber Imaging & Diagnostics

Caliber Imaging & Diagnostics' proprietary, cutting-edge VivaScope(R) system is a disruptive, noninvasive point-of-care platform imaging technology with numerous applications in dermatology, surgery and research. FDA 510(k) cleared, VivaScope has regulatory approval in most major markets. With 78 issued and pending patents worldwide, VivaScope has the potential to significantly improve outcomes and reduce costs. The VivaScan(TM) procedure, which utilizes the VivaScope for dermatological examination, allows physicians to detect cancerous lesions that appear benign, and reduces the need for expensive, painful and time-consuming biopsies, which show no malignancy approximately 70% of the time. VivaScope also has significant applications in testing and analysis in the academic, medical and therapeutic research markets. For more information about Caliber I.D. and its products, please visit www.caliberid.com.

VivaScope(R) is a registered trademark of Caliber Imaging & Diagnostics.

VivaScan(TM) is a trademark of Caliber Imaging and Diagnostics.

Safe Harbor

This press release contains "forward looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including the statements regarding the potential for future product revenue growth and financial performance. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed by us with the Securities and Exchange Commission.

CONTACT: Caliber Imaging & Diagnostics Richard Christopher Chief Financial Officer (617) 348-9821 rchristopher@caliberid.com or Dian Griesel Int'l. Susan Forman or Laura Radocaj (212) 825-3210 sforman@dgicomm.com lradocaj@dgicomm.comSource:Caliber Imaging & Diagnostics, Inc.